Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 100.00% is in line with its 5-year average of 94.14%, near the high end of its 5-year range (0.00%–100.00%).
25.00% above its 12-month average of 80.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
100.00%
GROSS MARGIN AVG TTM
80.00%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
94.14%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+25.00%
CURRENT VS 3Y AVG
0.00%
CURRENT VS 5Y AVG
+6.23%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 560 covered companies
CURRENT VS SECTOR MEDIAN
+133.05%
vs the sector median at left
Precision BioSciences, Inc.
Market Cap
$172.62M
Gross Margin
100.00%
TTM Avg
80.00%
3Y Avg
100.00%
5Y Avg
94.14%
Market Cap
$176.68M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
16.67%
Market Cap
$176.13M
Gross Margin
99.69%
TTM Avg
100.00%
3Y Avg
-73.48%
5Y Avg
-190.92%
Market Cap
$178.92M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$164.54M
Gross Margin
63.55%
TTM Avg
56.95%
3Y Avg
54.72%
5Y Avg
65.55%
Market Cap
$181.64M
Gross Margin
62.24%
TTM Avg
61.05%
3Y Avg
61.66%
5Y Avg
60.51%
Market Cap
$159.46M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
1.51%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Precision BioSciences, Inc. (DTIL) | $172.62M | 100.00% | 80.00% | 100.00% | 94.14% |
| MediWound Ltd. (MDWD)vs › | $172.65M | 15.46% | 16.11% | 25.27% | 28.77% |
| Compass Therapeutics, Inc. (CMPX)vs › | $176.68M | 0.00% | 50.00% | 25.00% | 16.67% |
| Cue Biopharma, Inc. (CUE)vs › | $176.13M | 99.69% | 100.00% | -73.48% | -190.92% |
| Canton Strategic Holdings Inc (CNTN)vs › | $178.92M | 0.00% | 0.00% | 0.00% | 0.00% |
| Coherus Oncology, Inc. (CHRS)vs › | $164.54M | 63.55% | 56.95% | 54.72% | 65.55% |
| Journey Medical Corporation (DERM)vs › | $181.64M | 62.24% | 61.05% | 61.66% | 60.51% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $159.46M | 0.00% | 0.00% | 0.00% | 1.51% |
| Inogen, Inc. (INGN)vs › | $159.74M | 48.89% | 46.84% | 43.63% | 44.77% |
| Anavex Life Sciences Corp. (AVXL)vs › | $157.54M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
100.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 100.00% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 84.48% |
| 2023-06-30 | 87.95% |
| 2023-03-31 | 74.05% |
| 2022-12-31 | 78.53% |
| 2022-09-30 | 69.48% |
| 2022-06-30 | 41.73% |
| 2022-03-31 | 31.99% |
| 2021-12-31 | 100.00% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 100.00% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
